XLO
Xilio Therapeutics, Inc.Company Information
- Company Name
- Xilio Therapeutics, Inc.
- CIK
- CIK0001840233
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- XLO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- XLO
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-26
- Last sale
- 2026-01-02
- Shares purchased (TTM)
- 66,289
- Shares sold (TTM)
- 8,856
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 2,743,016
- Shares outstanding
- 19,404,688
- Ownership
- 14.14%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -0.55%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 136 | 150 | 138 | 104 | 122 | 89 | 55 | 61 | 75 | 34 | 45 | 60 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 145 | 154 | 145 | 124 | 124 | 93 | 60 | 63 | 78 | 69 | 48 | 64 | ||||||
| Receivables Net Current | - | - | - | - | - | - | - | - | - | 30 | - | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 4 | 2 | 3 | 2 | 4 | 5 | 2 | 3 | 5 | 3 | 5 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | ||||||
| Property Plant And Equipment Net | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 6 | 6 | ||||||
| Operating Lease Right Of Use Asset | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Assets | 154 | 163 | 155 | 134 | 134 | 104 | 71 | 75 | 90 | 83 | 61 | 78 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 2 | 1 | 3 | 2 | 4 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 8 | 9 | 12 | 9 | 6 | 4 | 10 | 10 | 10 | 8 | 10 | 9 | ||||||
| Deferred Revenue Current | 23 | 32 | 40 | 44 | 42 | 40 | 14 | 26 | 27 | 22 | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 34 | 43 | 56 | 56 | 53 | 48 | 27 | 38 | 39 | 32 | 16 | 17 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 3 | 5 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Deferred Revenue Noncurrent | 13 | 16 | 21 | 25 | 29 | 39 | 19 | 8 | 10 | 17 | - | - | ||||||
| Operating Lease Liability Noncurrent | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | ||||||
| Warrants And Rights Outstanding | 30 | 26 | 30 | 54 | 39 | - | - | - | - | - | - | - | ||||||
| Liabilities | 82 | 91 | 119 | 142 | 127 | 93 | 53 | 54 | 56 | 57 | 24 | 25 | ||||||
| Common Stock Value | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 72 | 73 | 35 | -8 | 7 | 11 | 18 | 21 | 33 | 26 | 37 | 52 | ||||||
| Additional Paid In Capital | 507 | 501 | 454 | 421 | 420 | 408 | 401 | 392 | 390 | 368 | 362 | 360 | ||||||
| Retained Earnings Accumulated Deficit | -435 | -428 | -419 | -429 | -413 | -397 | -384 | -371 | -357 | -343 | -326 | -308 | ||||||
| Liabilities And Stockholders Equity | 154 | 163 | 155 | 134 | 134 | 104 | 71 | 75 | 90 | 83 | 61 | 78 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 600 | 600 | 600 | 600 | 600 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 7 | 6 | 5 | 52 | 52 | 52 | 3 | 44 | 44 | 34 | 28 | 28 | ||||||
| Shares Outstanding | 7 | 6 | 5 | 52 | 52 | 52 | 3 | 44 | 44 | 34 | 28 | 28 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialXilio Therapeutics, Inc. (XLO) — SEC Financial Statements & Analysis
Xilio Therapeutics, Inc. (XLO) is a pharmaceutical preparations company, incorporated in DE. Xilio Therapeutics, Inc. trades on Nasdaq as: XLO. Xilio Therapeutics, Inc. (XLO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Xilio Therapeutics, Inc. carries a market cap of $185.90M, a P/E ratio of -8.52x, a P/B ratio of 2.57x, a P/S ratio of 2.90x, an enterprise value of $48.04M, and an EV/EBITDA multiple of -1.60x. On profitability, it posts an operating margin of -48.94%, a net margin of -34.06%, a Return on Equity (ROE) of -55.03%, and a Return on Assets (ROA) of -15.16%. Per share, it reports EPS of $-1.12, diluted EPS of $-1.12, free cash flow per share of $-3.16, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 327.25% year-over-year, net income growth of -61.17% year-over-year, and EPS growth of -86.22% year-over-year. On the balance sheet, it maintains a current ratio of 4.25x, a quick ratio of 4.15x, working capital of $111.27M, a debt-to-equity ratio of 1.13x, a debt ratio of 0.53, free cash flow of $-61.27M (TTM), and net debt of $-137.86M. Figures sourced from SEC EDGAR.
- Market Cap
- $185.90M
- P/E TTM
- -8.52x
- EPS TTM
- $-1.12
- P/B TTM
- 2.57x
- ROE TTM
- -55.03%
- ROA TTM
- -15.16%
- Debt To Equity
- 1.13x
- Free Cash Flow TTM
- $-61.27M
- Net Revenue TTM Growth 1Y
- 327.25%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Xilio Therapeutics, Inc. in?
Xilio Therapeutics, Inc. (XLO) operates in the Pharmaceutical Preparations industry.
What exchange does XLO trade on?
Xilio Therapeutics, Inc. (XLO) trades on the Nasdaq.
Where is Xilio Therapeutics, Inc. incorporated?
Xilio Therapeutics, Inc. is incorporated in DE.
When was Xilio Therapeutics, Inc. (XLO)'s most recent SEC filing?
Xilio Therapeutics, Inc. (XLO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is XLO's market cap?
Xilio Therapeutics, Inc. (XLO) has a market capitalization of $185.90M as of 2026-06-30.
What is XLO's EPS (earnings per share)?
Xilio Therapeutics, Inc. (XLO)'s trailing twelve month EPS is $-1.12 as of 2026-06-30.
What is XLO's ROE (return on equity)?
Xilio Therapeutics, Inc. (XLO)'s trailing twelve month Return on Equity (ROE) is -55.03% as of 2026-06-30.
What is XLO's ROA (return on assets)?
Xilio Therapeutics, Inc. (XLO)'s trailing twelve month Return on Assets (ROA) is -15.16% as of 2026-06-30.
What is XLO's EV/EBITDA?
Xilio Therapeutics, Inc. (XLO)'s trailing twelve month EV/EBITDA is -1.60x as of 2026-06-30.